



ASCEND 8-Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

30/01/2025 22:34:27

Main Information

Primary registry identifying number

LBCTR2019121369

Protocol number

CLDK378A2112

MOH registration number

9537/ص

Study registered at the country of origin

Yes

Study registered at the country of origin: Specify

Type of registration

Retrospective

Type of registration: Justify

This study was previously submitted before LBCTR and still ongoing

Date of registration in national regulatory agency

22/10/2015

Primary sponsor

Novartis Pharma Services Inc

Primary sponsor: Country of origin

Novartis Pharma services Inc

Date of registration in primary registry

15/12/2020

Date of registration in national regulatory agency

22/10/2015

Public title

ASCEND 8-Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Acronym

Scientific title

A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Efficacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Acronym

Brief summary of the study: English

A Phase I study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

Brief summary of the study: Arabic

ملغ المأخوذ مع وجبة قليلة الدهون وفعاليتها 450 دراسة جزئية متعددة المراكز مفتوحة اللصاقة لتقييم التعرض الجهازى لدواء سيريتينيب ملغ المأخوذ على معدة فارغة لدى مرضى 750 ملغ المأخوذ مع وجبة قليلة الدهون مقارنة بدواء سيريتينيب 600 و سلامته ودواء سيريتينيب بالغين مصابين بسرطان الرئة النقلي غير ذي الخلايا الصغيرة، كيناز الورم اللمفي الكشمي المعاد ترتيبه (كيناز الورم اللمفي الكشمي الإيجابي)

Health conditions/problem studied: Specify





Metastatic non-small cell lung cancer (NSCLC)

Interventions: Specify

Drug: ceritinib

•Experimental: ceritinib 450 mg with a low-fat meal

Intervention: Drug: ceritinib

•Experimental: ceritinib 600 mg with a low-fat meal

Intervention: Drug: ceritinib

•Active Comparator: ceritinib 750 mg on an empty stomach

Intervention: Drug: ceritinib

Key inclusion and exclusion criteria: Inclusion criteria

Inclusion:

- 1.Histologically or cytologically confirmed diagnosis of stage IIIB (and is not a candidate for definitive multimodality therapy) or IV ALK-positive NSCLC.
- 2.Patients may have received one prior treatment regimen with crizotinib (all other ALK inhibitors are excluded).
- 3.Patients may have received prior chemotherapy, biologic therapy, or other investigational agents. ALK inhibitors other than crizotinib are excluded.
- 4.Patient has a World Health Organization (WHO) performance status 0-2.

Key inclusion and exclusion criteria: Gender

Both

Key inclusion and exclusion criteria: Specify gender

Key inclusion and exclusion criteria: Age minimum

18

Key inclusion and exclusion criteria: Age maximum

99

Key inclusion and exclusion criteria: Exclusion criteria

Exclusion:

- 1.Prior treatment with an ALK inhibitor other than crizotinib.
- 2.History of carcinomatous meningitis.
- 3.Presence or history of a malignant disease other than an ALK-positive advanced tumor that has been diagnosed and/or required therapy within the past 3 years.
5. Clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months)
6. Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).
7. Patient has other severe, acute, or chronic medical conditions
8. Patient is currently receiving treatment with warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants.

Type of study

Interventional

Type of intervention

Pharmaceutical

Type of intervention: Specify type

N/A

Trial scope

Pharmacokinetic

Trial scope: Specify scope

N/A

Study design: Allocation

Randomized controlled trial

Study design: Masking

Open (masking not used)

Study design: Control

Dose comparison

Study phase

1

Study design: Purpose

Treatment

Study design: Specify purpose

N/A

Study design: Assignment

Parallel

Study design: Specify assignment

N/A

IMP has market authorization

IMP has market authorization: Specify



No

Name of IMP

LDK378 (ceritinib)

Year of authorization

Month of authorization

Type of IMP

Cell therapy

Pharmaceutical class

5-Chloro-2-N-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-4-N-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine

Therapeutic indication

The study population will consist of previously treated and treatment-naive adult patients with metastatic ALK-positive NSCLC.

Therapeutic benefit

Overall Response Rate (ORR) and Duration of Response (DOR)

Study model

N/A

Study model: Explain model

N/A

Study model: Specify model

N/A

Time perspective

N/A

Time perspective: Explain time perspective

N/A

Time perspective: Specify perspective

N/A

Target follow-up duration

Target follow-up duration: Unit

Number of groups/cohorts

Biospecimen retention

Samples with DNA**

Biospecimen description

Samples are being shipped to a central Lab

Target sample size

5

Actual enrollment target size

5

Date of first enrollment: Type

Actual

Date of first enrollment: Date

10/02/2016

Date of study closure: Type

Actual

Date of study closure: Date

01/07/2020



Recruitment status Complete	Recruitment status: Specify
Date of completion 23/10/2017	
IPD sharing statement plan No	IPD sharing statement description not provided
Additional data URL https://clinicaltrials.gov/ct2/show/record/NCT02299505?term=ldk378&cntry=LB&draw=1&rank=4	
Admin comments	
Trial status Approved	

Secondary Identifying Numbers	
Full name of issuing authority	Secondary identifying number
Clinical trials.gov	NCT02299505

Sources of Monetary or Material Support
Name
Novartis Pharma Services Inc

Secondary Sponsors
Name
NA



Contact for Public/Scientific Queries

Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Marwan Ghosn	Beirut	Lebanon	03-226842	marwanghosnmd@yahoo.com	Hotel Dieu De France
Scientific	Hind Khairallah	Sinelfil	Lebanon	+961 1512002E xt. 271	Hind.Khairallah@fattal.com.lb	Khalil Fattal et Fils s.a.l.
Public	Fadi El Karak	Beirut	Lebanon	03-061621	felkarak@yahoo.com	Bellevue Medical Center

Centers/Hospitals Involved in the Study

Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Hotel Dieu De France	Marwan Ghosn	Hematology oncology	Approved
Bellevue Medical Center	Fadi El Karak	Hematology oncology	Approved

Ethics Review

Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Hotel Dieu de France	25/09/2015	Nancy Alam	nancy.alam@usj.edu.lb	+961 (0) 1 421000 ext 2335
Bellevue Medical Center	10/06/2016	Ghassan Maalouf	gmaalouf@bmc.com.lb	+961 (0) 1 682666 ext 7600



Countries of Recruitment	
Name	
Lebanon	
Australia	
Austria	
Belgium	
Brazil	
Bulgaria	
Canada	
Colombia	
Czech Republic	
Germany	
Greece	
India	
Italy	
Malaysia	
Netherlands	
Turkey	
United Kingdom	
United States of America	

Health Conditions or Problems Studied		
Condition	Code	Keyword
Metastatic non-small cell lung cancer (NSCLC)	Bronchus or lung, unspecified (C34.9)	Metastatic non-small cell lung cancer (NSCLC)



Interventions

Intervention	Description	Keyword
ICF, Lab tests, Vital signs , radiology, ECG	ICF, Lab tests, Vital signs , radiology, ECG	ICF, Lab tests, Vital signs , radiology, ECG

Primary Outcomes

Name	Time Points	Measure
Plasma concentration of ceritinib	Day 22	Day 22

Key Secondary Outcomes

Name	Time Points	Measure
Safety profile	12 weeks	12 weeks
Plasma concentration of ceritinib	Day 1	Day 1
•Duration of response (DOR)	every 6 weeks	every 6 weeks



Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files